GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Cyclically Adjusted PB Ratio

Medexus Pharmaceuticals (TSX:MDP) Cyclically Adjusted PB Ratio : 1.17 (As of May. 26, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Medexus Pharmaceuticals's current share price is C$1.63. Medexus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was C$1.39. Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 1.17.

The historical rank and industry rank for Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

TSX:MDP' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.79   Med: 4.57   Max: 11.37
Current: 1.17

During the past years, Medexus Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 11.37. The lowest was 0.79. And the median was 4.57.

TSX:MDP's Cyclically Adjusted PB Ratio is ranked better than
68.93% of 692 companies
in the Drug Manufacturers industry
Industry Median: 1.89 vs TSX:MDP: 1.17

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Medexus Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was C$1.622. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$1.39 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medexus Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Medexus Pharmaceuticals Annual Data
Trend Dec13 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 10.11 1.10

Medexus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.06 1.10 1.29 2.15 1.77

Competitive Comparison of Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Medexus Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.63/1.39
=1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Medexus Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.622/125.0724*125.0724
=1.622

Current CPI (Dec. 2023) = 125.0724.

Medexus Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201312 1.429 96.945 1.844
201406 1.392 99.473 1.750
201409 1.147 99.394 1.443
201412 0.960 98.367 1.221
201503 0.930 99.789 1.166
201506 0.634 100.500 0.789
201509 0.473 100.421 0.589
201512 0.239 99.947 0.299
201603 0.591 101.054 0.731
201606 0.894 102.002 1.096
201609 0.765 101.765 0.940
201612 0.571 101.449 0.704
201703 0.268 102.634 0.327
201706 0.922 103.029 1.119
201709 0.846 103.345 1.024
201712 0.705 103.345 0.853
201803 0.522 105.004 0.622
201806 0.410 105.557 0.486
201809 -0.193 105.636 -0.229
201812 3.828 105.399 4.543
201903 2.539 106.979 2.968
201906 2.357 107.690 2.737
201909 2.421 107.611 2.814
201912 2.152 107.769 2.498
202003 2.345 107.927 2.718
202006 1.900 108.401 2.192
202009 1.702 108.164 1.968
202012 0.380 108.559 0.438
202103 1.182 110.298 1.340
202106 0.731 111.720 0.818
202109 1.545 112.905 1.712
202112 1.485 113.774 1.632
202203 1.129 117.646 1.200
202206 1.127 120.806 1.167
202209 1.130 120.648 1.171
202212 1.041 120.964 1.076
202303 1.522 122.702 1.551
202306 1.489 124.203 1.499
202309 1.236 125.230 1.234
202312 1.622 125.072 1.622

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medexus Pharmaceuticals  (TSX:MDP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Medexus Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medexus Pharmaceuticals (TSX:MDP) Business Description

Traded in Other Exchanges
Address
35 Nixon Road, Suite 1, Bolton, ON, CAN, L7E 1K1
Medexus Pharmaceuticals Inc is an innovative and rare disease pharmaceutical company with a strong North American commercial platform and a portfolio of proven best-in-class products. The company's focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy.
Executives
Benoit Gravel Director